Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
diabetes mellitus
endothelial function
evolocumab
sodium-glucose transporter 2 inhibitors
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
06
2020
accepted:
21
08
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy may mitigate endothelial dysfunction in T2DM patients who are on regular treatment by SGLT2-i. The EXCEED-BHS3 is a prospective, single-center, investigator-blinded, open-label, randomized clinical trial. Participants ( This will be the first study to evaluate the add-on effect of PCSK9i on endothelial function of T2DM patients under regular use of empagliflozin. ClinicalTrials.gov identifier: NCT03932721.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with type 2 diabetes mellitus (T2DM) remain at increased cardiovascular residual risk and endothelial dysfunction, even after optimizing metabolic control and treatment by sodium-glucose-2 transporter inhibitors (SGLT2-is). The present study was based on the hypothesis that proprotein convertase subtilisin/kexin 9 inhibitor (PCSK9i) therapy may mitigate endothelial dysfunction in T2DM patients who are on regular treatment by SGLT2-i.
METHODS
METHODS
The EXCEED-BHS3 is a prospective, single-center, investigator-blinded, open-label, randomized clinical trial. Participants (
CONCLUSION
CONCLUSIONS
This will be the first study to evaluate the add-on effect of PCSK9i on endothelial function of T2DM patients under regular use of empagliflozin.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov identifier: NCT03932721.
Identifiants
pubmed: 33062236
doi: 10.1177/2040622320959248
pii: 10.1177_2040622320959248
pmc: PMC7534094
doi:
Banques de données
ClinicalTrials.gov
['NCT03932721']
Types de publication
Journal Article
Langues
eng
Pagination
2040622320959248Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Hypertension. 2019 Jul;74(1):208-215
pubmed: 31055952
J Biol Chem. 2000 Sep 15;275(37):28634-40
pubmed: 10893411
Arch Intern Med. 2008 Apr 14;168(7):721-7
pubmed: 18413554
Clin Diabetes. 2018 Jan;36(1):14-37
pubmed: 29382975
Diabetes. 2011 Oct;60(10):2617-23
pubmed: 21852676
JAMA. 1997 Mar 19;277(11):925-6
pubmed: 9062334
Circulation. 2012 Aug 7;126(6):753-67
pubmed: 22869857
Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1022-9
pubmed: 25657309
Lancet. 2008 Jan 12;371(9607):117-25
pubmed: 18191683
J Diabetes Investig. 2020 Mar;11(2):400-404
pubmed: 31361403
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur Heart J. 2019 Aug 7;40(30):2534-2547
pubmed: 31211361
N Engl J Med. 2016 Mar 17;374(11):1094
pubmed: 26981940
Cardiovasc Diabetol. 2012 Jun 13;11:67
pubmed: 22694800
J Atheroscler Thromb. 2020 Jul 1;27(7):644-656
pubmed: 31631099
J Lipid Res. 2018 Feb;59(2):207-223
pubmed: 29180444
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
J Lipid Res. 1981 Feb;22(2):339-58
pubmed: 6787159
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4253-4263
pubmed: 31162549
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950
pubmed: 28927706
J Lipid Res. 2018 Apr;59(4):714-721
pubmed: 29436385
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
J Diabetes. 2017 May;9(5):434-449
pubmed: 28044409
JAMA. 2013 Nov 20;310(19):2061-8
pubmed: 24240933
Circulation. 2007 Mar 13;115(10):1285-95
pubmed: 17353456
Curr Opin Lipidol. 2019 Apr;30(2):101-107
pubmed: 30672808
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Cardiovasc Diabetol. 2018 Dec 3;17(1):153
pubmed: 30509271
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):785-91
pubmed: 21273557
Diab Vasc Dis Res. 2020 Jan-Feb;17(1):1479164119883540
pubmed: 31726866
Circulation. 2009 Aug 11;120(6):502-9
pubmed: 19635967
Arterioscler Thromb Vasc Biol. 2017 Jul;37(7):1290-1300
pubmed: 28546220
Atherosclerosis. 2009 Jul;205(1):227-32
pubmed: 19150064
Cardiovasc Diabetol. 2019 Jun 5;18(1):76
pubmed: 31167663
Circulation. 2011 Jan 18;123(2):163-9
pubmed: 21200002
Am J Cardiol. 1999 May 15;83(10):1497-9, A8
pubmed: 10335771
Am J Transl Res. 2016 Feb 15;8(2):765-77
pubmed: 27158368